Benzinga | Oct 21, 2020 08:08AM EDT

Curis Highlights Publication In ACS Medicinal Chemistry Letters Showcasing Targeted Potency And Ideal Pharmacologic Properties Of CA-4948 For Treatment Of Hematologic Malignancies

LEXINGTON, Mass., Oct. 21, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today highlighted a paper published online in ACS Medicinal Chemistry Letters, a peer-reviewed publication of the American Chemical Society, titled, "Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies." The paper describes the preclinical work done to select CA-4948 and its on-target engagement and inhibition of IRAK4 in various animal studies. CA-4948 demonstrated potent IRAK4 inhibition, with favorable selectivity over other kinases, cellular activity, pharmacokinetics, efficacy, and safety, and showed tumor regression in a diffuse large B-cell lymphoma xenograft model without any overt toxicities.